Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A. The antiviral agent 4-GU-DANA (Zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus hemagglutinin. J Virol 2000; 74:11108-11114.

Horga M-A, Gusella G-L, Poltoratskaia N, Greengard O, Porotto M, Moscona A. The mechanism of viral interference mediated by human parainfluenza virus type 3. J Virol 2000; 74:11792-11799, 2000.

Murrell M, Greengard O, Porotto M, Poltoratskaia N, Moscona, A. A single amino acid alteration in the human parainfluenza virus type 3 HN confers resistance to both binding inhibition and neuramindiase inhibition by the antiviral agent 4-GU-DANA (Zanamivir). J Virol 2001; 75:6310-6320.

Porotto M, Greengard O, Poltoratskaia N, Horga M-A, Moscona A. Human parainfluenza virus type 3 HN-receptor interaction: the effect of 4-GU-DANA on a neuraminidase-deficient variant. J Virol 2001; 75:7481-7488.

Prince GA, Ottolini, MG, Moscona A. The contribution of the human parainfluenza virus 3 HN-receptor interaction to pathogenesis in vivo. J Virol 2001; 75:12446-12451.

Murrell, M, Porotto, M, Weber T, Greengard O, Moscona A.. Mutations in human parainfluenza virus type 3 HN causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (zanamivir). J Virol 2003; 77:309-317.

Porotto M, Greengard O, Murrell M, Moscona A. Triggering of human parainfluenza virus 3 fusion protein(F) by the hemagglutinin-neuraminidase (HN): an HN mutation diminishing the rate of F activation and fusion. J Virol 2003; 77:3647-3654.

Porotto M, Murrell M, Greengard O, Lawrence M, McKimm-Breschkin JL, Moscona A. Inhibition of parainfluenza type 3 and Newcastle disease virus hemagglutinin-neuraminidase receptor binding: Effect of receptor avidity and steric hindrance at the inhibitor binding sites. J Virol 78 (24): 13911-13919, 2004.

Moscona, A. Oseltamivir-resistant influenza? Lancet 364: 9436, 733-4, Aug. 2004.

Porotto M, Murrell M, Doctor, L., Greengard O, Moscona A. Influence of the human parainfluenza virus 3 attachment protein?s neuraminidase activity on its capacity to activate the fusion protein. J Virol. 79 (4): 2383-2392, 2005.

Moscona, A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. The Journal of Clinical Investigation 115: 1688-1698, 2005.

Moscona, A. Neuraminidase Inhibitors for Influenza. New England Journal of Medicine, 353:1363-1371, 2005.

Moscona, A. Oseltamivir resistance ? Disabling our influenza defenses. New Engl. Jl. Med. 353: 2634-2636, 2005.

Porotto, M., Fornabaio, M., Greengard, O., Murrell, M.T., Kellogg, G.E., and Moscona, A.. Paramyxovirus receptor-binding molecules: Engagement of one site on the hemagglutinin-neuraminidase modulates activity at the second site. Journal of Virology 80 (3), 1204-1213, 2006.

Loughlin GM and Moscona A. The cell biology of acute childhood respiratory disease: therapeutic implications. Pediatr Clin North Am. (5):929-59, 2006.

Delamora, P., and Moscona, A., A daring treatment and a successful outcome: The need for targeted therapies for pediatric respiratory viruses. Pediatr Transplant. 11(2):121-3, 2007.

Porotto, M., Doctor, L., Carta, P., Fornabaio, M., Greengard, O., Kellogg, GE and Moscona, A. Inhibition of Hendra virus membrane fusion. Journal of Virology 80 (19), 9837-9839, 2006.

Porotto, M., Fornabaio, M., Kellogg, GE and Moscona, A. A second receptor binding site on the human parainfluenza 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. Journal of Virology 81(7): 3216-28, 2007.

Porotto M, Doctor L, Carta P, Fornabaio M, Greengard O, Kellogg GE, and Moscona A. Inhibition of Hendra virus membrane fusion. Journal of Virology 80 (19), 9837-9839, 2006.

Porotto M, Fornabaio M, Kellogg GE, and Moscona A. A second receptor binding site on the human parainfluenza 3 hemagglutinin-neuraminidase contributes to activation of the fusion mechanism. Journal of Virology 81(7): 3216-28, 2007.

DeLaMora P and Moscona A. A daring treatment and a successful outcome: The need for targeted therapies for pediatric respiratory viruses. Pediatric Transplantation 11(2): 121-123, 2007.

Moscona A, McKimm-Breschkin J. News about influenza B drug resistance that cannot be ignored. Journal of the American Medical Association (JAMA) 2007 Apr 4;297(13):1492-3.

Palermo LM, Porotto M, Greengard O, and Moscona A. Fusion promotion by a paramyxovirus HN: modulation of receptor avidity of binding sites I and II by pH, J. Virol. 81 (17), 9152-9161, 2007 (Palermo and Porotto are co-first authors.)

Porotto, M., Carta, P, Deng, Y, Kellogg, GE, Whitt, M, Lu, M, Mungall, BA, Moscona, A. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. Journal of Virology 81 (19): 10567-74, 2007.

Moscona, A. CSI Microbiology: Emerging pathogens and a staged strategy for detection and discovery. Journal of Infectious Diseases 196: 1727-8, 2007.

Aljofan M, Porotto M, Moscona A, Mungall BA. Development and validation of a chemiluminescent immunodetection assay amenable to high throughput screening of antiviral drugs for Nipah and Hendra virus. J Virol Methods. 2008 Apr;149(1):12-9.